A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.

Also called NCT07654140

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 252 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07654140
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07654140. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-09 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
Condition
Uncontrolled Hypertension
Intervention (Drug)
SAL0140
Intervention (Drug)
SAL0140
Intervention (Drug)
SAL0140
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07654140
Content hash
ff21ee016ac1cdededc39f71f1b5031e4404bac0089ebc9225fb183f05d30fe9